CClinicalTrials.gg
Sign In
CompletedNCT06548776Updated Aug 31, 2026

Establishing Daily Applicable Parameters for Using Magnetic Resonance Spectroscopy of Spinal Cord

An interventional study of Magnetic Resonance Spectroscopy (MRS) Scan in Spinal Cord, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To learn if MRS can effectively assess spinal cord lesions.

Read the detailed description

Primary Objective:

Establish the feasibility and spectrum of MRS for adult patients while mapping the total spine spectrum at short TEs to allow for future comparison with patients to assess spinal cord lesions malignant potential and grade.

Secondary Objective:

Test success of the spectrum by implementing the protocol on 3 low volume LMD receiving LMD receiving CSI. This will allow us to test reproducibility of the protocol and test effect of radiation on spinal cord at different time frames. This will serve as secondary data for subsequent trials targeting functional statues after radiation and tumor grading predictability of MRS.

02

Conditions studied

  • Spinal Cord
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Volunteers:

  • Adults > 18 years
  • Healthy with no malignancy, demyelinating disease, back pain, degenerative disease, or spinal cord lesions.
  • Consent able patients.

Patients with low volume LMD to receive treatment CNS radiation:

  • Adults > 18 years old.
  • MR or CSF with evidence of LMD.
  • Patients to receive CSI as part of standard treatment of LMD disease.
  • Consent able patients, willingness and ability to comply with the study procedures.
  • No spinal cord lesions only LMD disease
  • Recruitment by radiation oncology faculty in consultation with Dr. De. . .

Exclusion criteria

Exclusion Criteria:

Volunteers:

  • Age \< 18 years
  • Pregnant or breastfeeding individuals.
  • History of cancer.
  • History of spinal cord lesions including malignant, demyelinating, or inflammatory.
  • History of prior spinal surgery.
  • History of implantable devices.
  • History of MR claustrophobia.
  • Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
  • Scoliosis.

Patients with LMD:

  • Age \< 18 years
  • History of spinal cord lesions including malignant, demyelinating, or inflammatory.
  • History of prior spinal surgery.
  • History of implantable devices.
  • History of MR claustrophobia.
  • Degenerative disease or spinal/back pain including myelopathy and radiculopathy.
  • Scoliosis.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Healthy Volunteers

    Participants will be recruited from DI volunteer pool to implement MRS spine on.

    Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) Scan

  • Experimental
    Patients

    Participants will be recruited from DI volunteer pool to implement MRS spine on.

    Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) Scan

Interventions

  • Diagnostic testMagnetic Resonance Spectroscopy (MRS) Scan

    Participants will receive MRS Scan

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 site
  • MD Anderson Cancer Center
    Houston, Texas 77090, United States
08

References and documents

Study documents

  • Informed consent form · May 6, 2025

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548776
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Sep 4, 2024
Primary completion
Aug 25, 2026
Completion
Aug 25, 2026
Last update
Aug 31, 2026

Study contacts

Rami Eldaya, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion